A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B302

Phase 4

Terminated

Interventions: Drug: EXPAREL (bupivacaine liposome injectable suspension)
Drug: IV morphine sulfate

Brief Summary: This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome extended-release injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total hospitalization costs.

Detailed Description: This is a phase 4, prospective, sequential, open-label study designed to evaluate the efficacy, safety, and health economic benefits of intraoperative local wound infiltration with EXPAREL (bupivacaine liposome extended-release injectable suspension), compared with postsurgical administration of standardized intravenous (IV) morphine sulfate, for postsurgical analgesia in adult patients undergoing open colectomy with general anesthesia.

Recruitment & Eligibility

Inclusion Criteria

Male or female, 18 years of age or older.
Patients scheduled to undergo open segmental colectomy with planned primary anastamosis, as defined by cecectomy, right hemicolectomy, resection of transverse colon, left hemicolectomy, or sigmoidectomy.
Ability to provide informed consent, adhere to study visit schedule, and complete all assessments.

Exclusion Criteria

Patients with a history of hypersensitivity or idiosyncratic reactions or intolerance to any local anesthetic, opioid, or propofol.
Patients who abuse alcohol or other drug substance.
Patients with severe hepatic impairment.
Patients currently pregnant or who may become pregnant during the course of the study.
Patients with any psychiatric, psychological, or other condition that the Investigator feels may make the patient an inappropriate candidate for this clinical study.
Patients who have participated in a EXPAREL study within the last 30 days.
Patients who have received an investigational drug within 30 days prior to study drug administration, or planned administration of another investigational product or procedure during the patient's participation in this study.
Patients who undergo any concurrent surgical procedure during the ileostomy reversal surgery.

In addition, the patient will be ineligible if he/she meets the following criteria during surgery:

Patients with unplanned multiple segmental resections or large intestine.
Patients who have unplanned, temporary or permanent colostomies, ileostomies, or the like placed.
Patients who receive intraoperative administration of opioids (other than fentanyl or analogs) or an other analgesic, local anesthetics, or anti-inflammatory agents.
Patients who receive Entereg(R).

Arm && Interventions

Group	Intervention	Description
EXPAREL	EXPAREL (bupivacaine liposome injectable suspension)	EXPAREL (bupivacaine liposome injectable suspension)
IV morphine sulfate	IV morphine sulfate	morphine sulfate (or Sponsor-approved equivalent)

Primary Outcome Measures

Name	Time	Method
Health Economic Benefits	Wound closure to Day 30	1. Total cost of hospitalization until the time hospital discharge order is written or through Day 30, whichever is sooner. 2. Length of stay (LOS), recorded in hours, defined as the time of completion of the wound closure until the hospital discharge order is written or through Day 30, whichever is sooner.
Total Opioid Burden	Wound closure to time hospital discharge order written or Day 30, whichever is sooner	Total opioid consumed (IV and PO) postsurgically until the hospital discharge order is written or through Day 30, whichever is sooner.

Secondary Outcome Measures

Name	Time	Method
Incidence of Opioid-related Adverse Events and Patient Satisfaction With Postsurgical Analgesia.	Wound closure to time hospital discharge order written or Day 30, whichever is sooner.	1. Incidence of opioid-related adverse events defined as somnolence, respiratory depression, hypoventilation, hypoxia, dry mouth, nausea, vomiting, constipation, sedation, confusion, pruritus, urinary retention, and postoperative ileus. 2. Responses to one question pertaining to patient satisfaction with postsurgical analgesia and four questions pertaining to postsurgical recovery following hospital discharge.